Linscott Walt Addison
Known title: Chief Business OfficerCIK: 0001648585
Linscott Walt Addison's purchase track record
Linscott Walt Addison has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/7/2022 | INDP | $393 | -24.8% | -37.0% | +0.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INDP | ▲ Buy | Grant | 54,421 | $110K | 12/22/2025 | View on chart |
| INDP | ▲ Buy | Open Market | 150 | $393 | 9/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Indaptus named among top small-cap healthcare performers
Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.
Indaptus named among top small-cap healthcare performers. Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.